A high mutation rate of immunoglobulin heavy chain variable region gene associates with a poor survival and chemotherapy response of mantle cell lymphoma patients.
Journal
Medicine
ISSN: 1536-5964
Titre abrégé: Medicine (Baltimore)
Pays: United States
ID NLM: 2985248R
Informations de publication
Date de publication:
May 2019
May 2019
Historique:
entrez:
31
5
2019
pubmed:
31
5
2019
medline:
14
6
2019
Statut:
ppublish
Résumé
Immunoglobulin heavy chain variable region (IGHV) gene mutation status is a biomarker for the prognosis of chronic lymphocytic leukemia, whether it is associated with the diagnosis, staging, and prognosis of patients with mantle cell lymphoma (MCL) remains to be determined.The IGHV gene mutations of 52 MCL patients were determined by DNA sequencing and compared with published IGHV germline sequences.DNA sequence alignment of IGHV variable regions with published IGHV germline sequences showed that the coincidence rate was 94% to 100%. Ten cases (21%) were significantly mutated with the rate of 96.9% to 94.0%. The overall survival time of patients was negatively correlated with the degree of IGHV gene mutation. Further survival analysis with log-rank test demonstrated that the patients with significant IGHV gene mutations showed a trend towards poor survival.The mutation rate of the IGHV variant region may be determined to assess the prognosis and overall survival time of MCL patients.
Identifiants
pubmed: 31145313
doi: 10.1097/MD.0000000000015811
pii: 00005792-201905310-00043
pmc: PMC6708879
doi:
Substances chimiques
Antineoplastic Agents
0
Immunoglobulin Heavy Chains
0
Immunoglobulin Variable Region
0
Types de publication
Journal Article
Observational Study
Langues
eng
Sous-ensembles de citation
IM
Pagination
e15811Références
Blood. 2015 Jan 1;125(1):48-55
pubmed: 25499451
Blood. 2014 Feb 6;123(6):884-93
pubmed: 24352880
Blood. 2014 Aug 21;124(8):1259-65
pubmed: 25016003
Mol Cancer Ther. 2013 Oct;12(10):2006-17
pubmed: 23963361
Cancer. 2014 Jul 1;120(13):1993-9
pubmed: 24706502
Haematologica. 2012 Sep;97(9):1422-30
pubmed: 22315488
Cancer Res. 2012 Oct 15;72(20):5307-16
pubmed: 22915760
Acta Haematol. 2013;129(4):207-14
pubmed: 23295437
Clin Cancer Res. 2014 Feb 15;20(4):1007-19
pubmed: 24352646
Leuk Lymphoma. 2008 Jun;49(6):1042-9
pubmed: 18452063
Leukemia. 2015 Feb;29(2):346-55
pubmed: 24947019
Mol Ther. 2013 Nov;21(11):2019-31
pubmed: 23913184
Int J Hematol. 2016 Feb;103(2):219-26
pubmed: 26588928
Br J Haematol. 2018 Jan;180(1):33-40
pubmed: 29164608
Mol Cancer Ther. 2013 Nov;12(11):2494-504
pubmed: 23990113
J BUON. 2014 Apr-Jun;19(2):342-9
pubmed: 24965390
J Mol Diagn. 2007 Feb;9(1):47-54
pubmed: 17251335
Blood. 2014 Jul 17;124(3):412-9
pubmed: 24891323
Blood. 2014 Mar 27;123(13):2044-53
pubmed: 24452204
Am J Pathol. 2013 Apr;182(4):1092-8
pubmed: 23375451
J Clin Invest. 2012 Oct;122(10):3416-23
pubmed: 23023712